In a solid win for Valeant Pharmaceuticals International Inc., the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted 18-0 in favor of approving the biologics license application (BLA) for brodalumab, branded Siliq, to treat adults with moderate to severe plaque psoriasis.